Short answer
Natera Inc (NTRA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 results for quarter ended September 30, 2026 announced November 5, 2026.
Natera Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 announced November 5, 2026
- Investor presentation furnished alongside earnings release, providing supplemental operating and financial detail
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $794.0M, up 34.1% YoY, with reported tests up 23.0% to 1,024,800
- Oncology tests 339,500, up 60.9% YoY, while clinical MRD units grew 32,700 sequentially
- Gross margin 64.7% versus 64.9% YoY, with non-GAAP margin up 1.4% sequentially excluding revenue-accrual changes
- Net loss narrowed to $59.9M, or $0.42 per share, from $87.5M, or $0.64 per share
- 2026 revenue guidance raised to $3.005B-$3.035B, with positive cash flow expected
Item EX-99.2 · Exhibit EX-99.2
- Q3 2026 revenue $794.0M, up ~34% year over year, with total tests exceeding 1.09M
- Clinical MRD oncology volume ~316K, up >56% year over year and ~33K sequentially
- Gross margin 64.7%, while ex-true-up margin reached 63.2%, up ~140 basis points sequentially
- 2026 revenue guidance raised to $3.005B-$3.035B, a $140M midpoint increase
- 2029 revenue target of $6B, supported by oncology, Japan expansion, pharma partnerships, and data licensing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Natera Inc 8-K filings
Get the next NTRA 8-K as it lands
Follow NTRA for push alerts, or ask the research agent what this filing means.